


## Berenberg European Conference 2018

December 5, 2018



#### CARDIOVASCULAR

#### Safe Harbor

Certain statements in this presentation, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "should," "expect," "anticipate," "estimate," "plan," "intend," "forecast," "foresee" or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking statements contained in this presentation, including those described in the "Risk Factors" section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova. All information in this presentation is as of the date of its release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this presentation to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this presentation.

## Intellectual Property

This report may contain references to our proprietary intellectual property, including among others:

Trademarks for our Neuromodulation systems, the VNS Therapy<sup>®</sup> System, the VITARIA<sup>®</sup> System and our proprietary pulse generator products: Model 102 (Pulse<sup>®</sup>), Model 102R (Pulse Duo<sup>®</sup>), Model 103 (Demipulse<sup>®</sup>), Model 104 (Demipulse Duo<sup>®</sup>), Model 105 (AspireHC<sup>®</sup>), Model 106 (AspireSR<sup>®</sup>) and Model 1000 (SenTiva<sup>®</sup>).

Trademarks for our Cardiopulmonary product systems: S5<sup>®</sup> heart-lung machine, S3<sup>®</sup> heart-lung machine, Inspire<sup>™</sup>, Heartlink<sup>™</sup>, XTRA<sup>®</sup> Autotransfusion System, 3T Heater-Cooler<sup>®</sup> and Connect<sup>™</sup>.

Trademarks for our line of surgical tissue and mechanical heart valve replacements and repair products: Mitroflow<sup>™</sup>, Crown PRT<sup>™</sup>, Solo Smart<sup>™</sup>, Perceval<sup>®</sup>, Top Hat<sup>™</sup>, Reduced Series Aortic Valves<sup>™</sup>, Carbomedics Carbo-Seal<sup>™</sup>, Carbo-Seal Valsalva<sup>™</sup>, Carbomedics Standard<sup>™</sup>, Orbis<sup>™</sup> and Optiform<sup>™</sup>, and Mitral valve repair products: Memo 3D<sup>™</sup>, Memo 3D ReChord<sup>™</sup>, AnnuloFlo<sup>™</sup> and AnnuloFlex<sup>™</sup>.

These trademarks and tradenames are the property of LivaNova or the property of our consolidated subsidiaries and are protected under applicable intellectual property laws. Solely for convenience, our trademarks and tradenames referred to in this presentation may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames.

#### We are a \$1.0B<sup>1</sup> focused medical innovator

#### Improving quality of patients' lives


Strong leadership position in Neuromodulation and Cardiovascular Targeting underserved and high-growth market segments



## With leading positions in neuromodulation and cardiovascular 3018: \$272M

Drug-Resistant Epilepsy (DRE) Treatment-Resistant Depression (TRD) Obstructive Sleep Apnea (OSA)

Vagus Nerve Stimulation Therapy (VNS Therapy) Hypoglossal Nerve Stimulation Therapy (HGNS Therapy)



Numbers may not add up precisely due to rounding.

\* Percent change performance is shown on a year-over-year constant currency basis, which is a non-GAAP measure. Constant currency eliminates the effects of foreign currency fluctuations.

### Our portfolio is focused on "Head & Heart"

	NEUROMODULATION	CARDIOVASCULAR	
		CARDIOPULMONARY	HEART VALVES
	Creator, leader of VNS Therapy	Market-leading positions	Only sutureless valve on the market
Global Market (2017)	\$4.1B	\$3.0B	\$1.7B
Market Growth	Low-double-digit	Mid-single-digit	Low-single-digit
Sales (2017)	\$375M1	\$500M <sup>2</sup>	\$140M
Disease State	Drug-Resistant Epilepsy Treatment-Resistant Depression Obstructive Sleep Apnea	Heart valve disease Coronary disease Congenital heart defect Heart Failure CGS, High-risk PCI, RVF, ARDS, SCA <sup>3</sup>	
Customers	Neurologists Epileptologists Psychiatrists Neurosurgeons ENT Specialists	Perfusionists Intensivists Cardiac Surgeons Cardiologists Interventional Cardiologists	

<sup>1</sup> Obstructive Sleep Apnea resides under Neuromodulation and was acquired in January 2018. Sales are not included as part of LivaNova's 2017 revenues.


<sup>2</sup> Advanced Circulatory Support resides under Cardiopulmonary and was acquired in April 2018. Sales are not included as part of LivaNova's 2017 revenues.

<sup>3</sup> CGS=Cardiogenic Shock; PCI=Percutaneous Coronary Intervention; RVF=Right Ventricular Failure; ARDS=Acute Respiratory Distress Syndrome; SCA=Sudden Cardiac Arrest Numbers are rounded for presentation purposes

#### LivaNova

6

### Multiple near-term growth drivers



## Differentiated pipeline targeting medical conditions with high unmet needs

TREATMENT- RESISTANT DEPRESSION (TRD)	OBSTRUCTIVE SLEEP APNEA (OSA)	TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR)	HEART FAILURE (HF)
VNS Therapy may provide better outcomes and symptom improvement	Implantable pulse generator (IPG) opens the airway during sleep	Unique transseptal investigational device	Novel delivery of Autonomic Regulation Therapy (ART) may improve regulation of cardiovascular function
Depression is the leading cause of disability worldwide	Rapidly growing multi- billion dollar market	Potentially 2-3 times the size of the TAVR market opportunity	Leading cause of morbidity and mortality

## Full-year 2018 Guidance from Continuing Operations

Reaffirming EPS guidance resulting from improved sales growth, gross margin and tax offset by higher investments in SG&A and R&D

	Guidance as of May 2, 2018	Guidance as of October 31, 2018
Worldwide net sales growth <sup>(1)</sup>	6% - 8%	7% - 9%
Gross margin <sup>(1)</sup>	66% - 68%	67.5% - 68.5%
R&D <sup>(1)</sup>	11% - 13%	12% - 13%
SG&A <sup>(1)</sup>	34% - 36%	35.5% - 36.5%
Operating margin <sup>(1)</sup>	19% -21%	19% -21%
Effective tax rate	18% - 20%	16% - 18%
Diluted EPS <sup>(1) (2)</sup>	\$3.50 - \$3.70	\$3.50 - \$3.70
Cash flow from operations <sup>(3)</sup>	\$180M - \$200M	\$180M - \$200M

1. Net sales are on a constant currency basis. All financial measures are adjusted non-GAAP measures.

2. Diluted EPS assumes a share count of approximately 49 million.

Excludes integration, restructuring and product remediation payments.

## Accelerating Growth While Investing in our Future

Performing	<ul> <li>\$1B focused medical innovator</li> <li>Strong leadership position in Neuromodulation and Cardiovascular</li> <li>Targeting ~\$9B global market opportunities</li> <li>Increasing sales and growing margins</li> </ul>
Transforming	<ul> <li>Three acquisitions in the past 18 months – Caisson, ImThera and TandemLife</li> <li>Targeting large and growing markets with high unmet needs</li> <li>Aligned with our focus on "head and heart"</li> <li>Making targeted M&amp;A decisions; mix of accretive and dilutive acquisitions</li> <li>Divested our CRM business to MicroPort for \$190M in April 2018</li> </ul>
Growing	<ul> <li>Building a robust product pipeline in core areas of leadership and strength</li> <li>Developing next-generation products to better serve patient needs</li> <li>Advancing multiple clinical trials in North America and Europe</li> <li>Executing funnel management &amp; profitability initiatives to increase sales and margins</li> <li>Leveraging our global footprint and capabilities</li> </ul>

# LivaNova

Health innovation that matters